$BMY – this deucra / Sotyktu approval changes profile of terminal value completely (bad for $AMGN)
Key bear thesis on Bristol Myers Squibb had been massive loss of exclusivity problem - coming from Revlimid ($10bn franchise) and Eliquis ($6bn) franchise with no material pipeline asset to…